logo
Octopuses' 8 Arms Snoop on the Microbial World

Octopuses' 8 Arms Snoop on the Microbial World

New York Times17-06-2025
When octopuses extend their eight arms into hidden nooks and crannies in search of a meal, they are not just feeling around in the dark for their food. They are tasting their prey, and with even more sensory sophistication than scientists had already imagined.
Researchers reported on Tuesday in the journal Cell that octopus arms are fine-tuned to 'eavesdrop into the microbial world,' detecting microbiomes on the surfaces around them and deriving information from them, said Rebecka Sepela, a molecular biologist at Harvard and an author of the new study.
Where octopus eyes cannot see, their arms can go to identify prey and make sense of their surroundings. Scientists knew that those eight arms (not tentacles) sense whether their eggs are healthy or need to be pruned. And the hundreds of suckers on each arm have over 10,000 chemotactile sensory receptors each, working with 500 million neurons to pick up that information and relay it throughout the nervous system.
Yet, what exactly the octopus is tasting by probing and prodding — and how its arms can distinguish, say, a rock from an egg, a healthy egg in its clutch from a sick one or a crab that's safe to eat from a rotting, toxic one — has long baffled scientists.
What about the surfaces are they perceiving?
For Dr. Sepela, this question was heightened when her team discovered 26 receptors along the octopuses' arms that didn't have a known function. She supposed those receptors were tuned only to molecules found on surfaces, rather than those diffused in water.
So she and her colleagues collected swaths of molecules coating healthy and unhealthy crabs and octopus eggs. They grew and cultured the microbes from those surfaces in the lab, then tested 300 microbial strains, one by one, on two of those 26 receptors.
Want all of The Times? Subscribe.
Orange background

Try Our AI Features

Explore what Daily8 AI can do for you:

Comments

No comments yet...

Related Articles

Record number of injured birds brought in to University of Minnesota's Raptor Center
Record number of injured birds brought in to University of Minnesota's Raptor Center

CBS News

time28 minutes ago

  • CBS News

Record number of injured birds brought in to University of Minnesota's Raptor Center

The University of Minnesota's Raptor Center says a record number of birds are being brought in for injuries. "It's been a record-setting year. And last year was a record-setting year," said Interim Executive Director Lori Arendt. During the summer months, it's not unusual to see an uptick in eagles, owls, and hawks being brought into the U of M's Raptor Center. What is unusual is the record pace at which they're being brought in. "This morning, we were at 679 for the year. And last year we were at about 550," said Arendt. "We have birds that are hit by cars, by windows, that get caught in buildings and are hit by ceiling fans." Arendt said weather is a big part of the uptick. A milder winter means more mice. And more mice means more food for raptors, which in turn, means the population soars. "Our baby season has just been really, really busy," said Arendt. Those same chicks have fallen victim to storms and high winds, which have knocked down raptor nests. The wet spring can be blamed for more cases of West Nile Virus among the birds. Some mosquitoes carry the virus and they've been thriving in this weather. "We've already admitted more than 40 birds that we suspect have succumbed to the virus," said Arendt. The Raptor Center said their facilities are nearly full, workers are getting overtime, and they are relying on volunteers to fill the gaps. With more birds coming into contact with vehicles and viruses, Arendt thinks this could be a sign of things to come. "We are really looking at how can we be prepared for this higher case load and higher number or raptors that we are admitting to our hospital. How can we be proactive, so we are better prepared for it," said Arendt. As of May 31, the Raptor Center had 80 raptor babies admitted into their clinic, which is 30 more than their record high during the spring of 2023.

Elon Musk's Company Achieves Major Breakthrough
Elon Musk's Company Achieves Major Breakthrough

Yahoo

time42 minutes ago

  • Yahoo

Elon Musk's Company Achieves Major Breakthrough

Elon Musk's Neuralink is continuing to make advancements, with the company achieving a first over the weekend. According to Neuralink, it has successfully implanted its brain-computer interface (BCI) in its eighth and ninth participants. In addition, Neuralink revealed that both implants were done on the same day, which had never been done before. "We successfully completed both P8 and P9 this weekend, our first time performing two surgeries in one day," Neuralink wrote. "Both participants are recovering well and in great spirits. We are looking forward to supporting them on their Neuralink journey." Neuralink has already helped paraplegics in clinical trials, with the BCI chip enabling them to control a computer and robot arms with their thoughts. The hope is that one day the device will help those same people walk again. But Musk also believes the implant will help those who are deaf or hard of hearing and others with dementia down the road. "Neuralink will do life-changing good for ultimately millions, maybe billions, of people," Musk predicted. "Imagine your loved one being able to walk again or your parent with dementia being able to recognize their child again." Completing two surgeries in one day is a big step for Neuralink, as now it'll be possible for the company to help more people in a shorter amount of time. Whether or not Neuralink's device will be able to do what Musk says remains to be seen, but it's moving in the right Musk's Company Achieves Major Breakthrough first appeared on Men's Journal on Jul 21, 2025

Biogen to Highlight Scientific Progress Across Alzheimer's Disease at the Alzheimer's Association International Conference 2025
Biogen to Highlight Scientific Progress Across Alzheimer's Disease at the Alzheimer's Association International Conference 2025

Yahoo

timean hour ago

  • Yahoo

Biogen to Highlight Scientific Progress Across Alzheimer's Disease at the Alzheimer's Association International Conference 2025

Lecanemab presentations to include long-term Clarity AD data, real-world treatment insights, and a subcutaneous formulation for continued care Presentations on tau to explore its biological role, the development of targeted therapies and biomarkers, and the future integration of these innovations into clinical practice CAMBRIDGE, Mass., July 21, 2025 (GLOBE NEWSWIRE) -- Biogen Inc. (Nasdaq: BIIB) today announced upcoming scientific presentations at the 2025 Alzheimer's Association International Conference (AAIC), taking place July 27-31 in Toronto, Canada. Data on LEQEMBI® (lecanemab) will include 48-month results from the Clarity AD open-label extension, real-world evidence, and new insights into a subcutaneous formulation for maintenance dosing. Presentations on tau will explore tau-targeted therapies and biomarkers, including baseline characteristics of participants from CELIA, a Phase 2 trial evaluating the efficacy, safety, and tolerability of BIIB080, an investigational antisense oligonucleotide (ASO) therapy that targets tau. 'At AAIC, we are sharing data that underscore our ongoing efforts to advance both how Alzheimer's is treated and how care is delivered, including 48-month findings from the LEQEMBI Clarity AD open-label extension and new insights into the potential of subcutaneous maintenance dosing for LEQEMBI. We are also excited to share baseline characteristics from CELIA, our Phase 2 study of BIIB080, an investigational ASO therapy targeting tau,' said Priya Singhal, M.D., M.P.H., Head of Development at Biogen. 'As we deepen our understanding of this complex disease, we remain committed to pushing the science forward and evolving care to better meet the needs of patients and families.' Key Scientific Sessions and Presentations: Lecanemab Clarity AD OLE in Early AD: Initial Findings from 48-Month AnalysisWednesday, July 30, 8:00–8:45 AM ET Lecanemab Subcutaneous Formulation for Maintenance Dosing: The Potential of a New and Convenient Option for Ongoing Treatment in Early Alzheimer's DiseaseWednesday, July 30, 9:00–10:30 AM ET Patient, Care Partner, and Health Care Professional Opinion of the Lecanemab Autoinjector for Subcutaneous DeliverySunday, July 27, 8:00–8:45 AM ET Lecanemab Two Years Post-Approval: Real-World Case Series and Patient Pathway LearningsSunday, July 27, 9:00–10:30 AM ET Indirect Treatment Comparison of ARIA Outcomes for Lecanemab Compared to Donanemab Based on Reported ResultsSunday, July 27, 4:14–5:45 PM ET Innovations in Tau Therapies and Biomarkers for Alzheimer's Disease: Bridging Research and Clinical PracticeWednesday, July 30, 2:00–3:30 PM ET Baseline Characteristics from CELIA: A Phase 2 Study to Evaluate BIIB080 in Participants with Early Alzheimer's DiseaseMonday, July 28, 7:30 AM–4:15 PM ET Educational Program on Tau in Alzheimer's Disease At AAIC, Biogen will host an interactive booth offering an immersive journey into the role of tau in Alzheimer's disease, from pathology to clinical presentation. Biogen is also expanding its educational efforts with a new e-learning module on building on the resources already available. For more information, please see the AAIC 2025 program and visit the Biogen AAIC booth. About BIIB080BIIB080 is an investigational antisense oligonucleotide (ASO) therapy designed to target microtubule-associated protein tau (MAPT) mRNA to reduce the production of tau protein. Abnormal accumulation of tau in the brain is a hallmark of Alzheimer's disease and is associated with neurodegeneration and cognitive decline. BIIB080 is currently being evaluated in a Phase 2 clinical study (NCT05399888) in individuals with early Alzheimer's disease. In December 2019, Biogen exercised a license option with Ionis Pharmaceuticals and obtained a worldwide, exclusive, royalty-bearing license to develop and commercialize BIIB080 (tau ASO). BIIB080 was discovered by Ionis. About LEQEMBI ® (lecanemab)LEQEMBI (lecanemab) is the result of a strategic research alliance between Eisai and BioArctic. LEQEMBI is a humanized immunoglobulin gamma 1 (IgG1) monoclonal antibody directed against aggregated soluble (protofibril) and insoluble forms of amyloid-beta (Aβ). LEQEMBI is an amyloid beta-directed antibody for the treatment for Alzheimer's disease (AD) in the U.S. The U.S. Food and Drug Administration (FDA) granted LEQEMBI traditional approval on July 6, 2023. LEQEMBI is indicated for the treatment of Alzheimer's disease. Treatment with LEQEMBI should be initiated in patients with mild cognitive impairment or mild dementia stage of disease, the population in which treatment was initiated in clinical trials. Eisai and Biogen have been collaborating on the joint development and commercialization of AD treatments since 2014. Eisai serves as the lead of LEQEMBI development and regulatory submissions globally with both companies co-commercializing and co-promoting the product and Eisai having final decision-making authority. Please see full U.S. Prescribing Information for LEQEMBI, including Boxed WARNING and Medication Guide. About BiogenFounded in 1978, Biogen is a leading biotechnology company that pioneers innovative science to deliver new medicines to transform patients' lives and to create value for shareholders and our communities. We apply deep understanding of human biology and leverage different modalities to advance first-in-class treatments or therapies that deliver superior outcomes. Our approach is to take bold risks, balanced with return on investment to deliver long-term routinely post information that may be important to investors on our website at Follow us on social media - Facebook, LinkedIn, X, YouTube. Biogen Safe Harbor This news release contains forward-looking statements, including about the potential clinical effects of lecanemab and BIIB080; the potential benefits, safety and efficacy of lecanemab and BIIB080; potential regulatory discussions, submissions and approvals and the timing thereof; the treatment of Alzheimer's disease; the anticipated risks, benefits and potential of Biogen's collaboration arrangements with Eisai; the potential of Biogen's commercial business and pipeline programs, including lecanemab and BIIB080; and risks and uncertainties associated with drug development and commercialization. These forward-looking statements may be accompanied by such words as 'aim,' 'anticipate,' 'assume,' 'believe,' 'contemplate,' 'continue,' 'could,' 'estimate,' 'expect,' 'forecast,' 'goal,' 'guidance,' 'hope,' 'intend,' 'may,' 'objective,' 'plan,' 'possible,' 'potential,' 'predict,' 'project,' 'prospect,' 'should,' 'target,' 'will,' 'would,' and other words and terms of similar meaning. Drug development and commercialization involve a high degree of risk, and only a small number of research and development programs result in commercialization of a product. Results in early-stage clinical trials may not be indicative of full results or results from later stage or larger scale clinical trials and do not ensure regulatory approval. You should not place undue reliance on these statements. Given their forward-looking nature, these statements involve substantial risks and uncertainties that may be based on inaccurate assumptions and could cause actual results to differ materially from those reflected in such statements. These forward-looking statements are based on management's current beliefs and assumptions and on information currently available to management. Given their nature, we cannot assure that any outcome expressed in these forward-looking statements will be realized in whole or in part. We caution that these statements are subject to risks and uncertainties, many of which are outside of our control and could cause future events or results to be materially different from those stated or implied in this document, including, among others, uncertainty of long-term success in developing, licensing, or acquiring other product candidates or additional indications for existing products; expectations, plans and prospects relating to product approvals, approvals of additional indications for our existing products, sales, pricing, growth, reimbursement and launch of our marketed and pipeline products; our ability to effectively implement our corporate strategy; risks associated with third party collaborations; the risk that positive results in a clinical trial may not be replicated in subsequent or confirmatory trials or success in early stage clinical trials may not be predictive of results in later stage or large scale clinical trials or trials in other potential indications; risks associated with clinical trials, including our ability to adequately manage clinical activities, unexpected concerns that may arise from additional data or analysis obtained during clinical trials, regulatory authorities may require additional information or further studies, or may fail to approve or may delay approval of our drug candidates; the occurrence of adverse safety events, restrictions on use with our products, or product liability claims; risks of unexpected costs or delays or other unforeseen hurdles; and any other risks and uncertainties that are described in other reports we have filed with the U.S. Securities and Exchange Commission. These statements speak only as of the date of this press release and are based on information and estimates available to us at this time. Should known or unknown risks or uncertainties materialize or should underlying assumptions prove inaccurate, actual results could vary materially from past results and those anticipated, estimated or projected. Investors are cautioned not to put undue reliance on forward-looking statements. A further list and description of risks, uncertainties and other matters can be found in our Annual Report on Form 10-K for the fiscal year ended December 31, 2024 and in our subsequent reports on Form 10-Q and Form 10-K, in each case including in the sections thereof captioned 'Note Regarding Forward-Looking Statements' and 'Item 1A. Risk Factors,' and in our subsequent reports on Form 8-K. Except as required by law, we do not undertake any obligation to publicly update any forward-looking statements whether as a result of any new information, future events, changed circumstances or otherwise. MEDIA CONTACT:BiogenMadeleine Shin+ 1 781 464 INVESTOR CONTACT:BiogenTim Power+1 781 464 2442IR@ Se produjo un error al recuperar la información Inicia sesión para acceder a tu portafolio Se produjo un error al recuperar la información Se produjo un error al recuperar la información Se produjo un error al recuperar la información Se produjo un error al recuperar la información

DOWNLOAD THE APP

Get Started Now: Download the App

Ready to dive into a world of global content with local flavor? Download Daily8 app today from your preferred app store and start exploring.
app-storeplay-store